Back to search results

Study of BMS-986460 for Metastatic Castration-resistant Prostate Cancer

This study is testing a drug called BMS-986460 for men with metastatic castration-resistant prostate cancer. This is prostate cancer that has spread to other parts of the body and is no longer responding to standard hormone therapy. The main goals are to understand how safe BMS-986460 is and how well people tolerate it, as well as to see its early effects. You might be able to join if you are a man, 18 or older, with confirmed prostate cancer that has spread and progressed after hormone therapy. Your PSA (prostate specific antigen) level must be 2 ng/mL or higher. The study plans to enroll about 140 participants. The current recruitment status is unclear.

Study design
This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll about 140 men.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be monitored for adverse events (side effects) for up to 112 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06067841

A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer

Recruiting
PHASE1Ages 18+InterventionalTreatment
Bristol-Myers Squibb
~140 participants
Updated 2026-08-10 on ClinicalTrials.gov
What's tested:BMS-986460

At a glance

Recruiting sites
10 of 15 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of participants with adverse events (AEs)
Measured over Up to 112 weeks
+4 more outcomes measured

Conditions

Metastatic Castration-resistant Prostate Cancer

Explore related trials

Prostate CarcinomaKLK3 Gene

Where it's being run

15 sites across 14 states
Texas2
California1
Florida1
Massachusetts1
New York1
North Carolina1
Washington1
Ontario1

Study leadership

  • Bristol-Myers Squibb · STUDY_DIRECTOR · Bristol-Myers Squibb

Who to contact

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
[email protected]
855-907-3286
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Participant must have histologically or cytologically confirmed adenocarcinoma of the prostate.
Participant must have an Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1.
Participant must have prostate specific antigen (PSA) of ≥ 2 ng/mL at Screening
Participant must have progressed on androgen deprivation therapy (ADT) and at least one prior secondary hormonal therapy approved for castration-resistant prostate cancer (CRPC)

Exclusion

Participant must not have history of brain metastases.
Participant must not have impaired cardiac function or clinically significant cardiac disease.
Participant must not have any significant medical condition, including active or uncontrolled infection, psychiatric illness, or the presence of laboratory abnormalities, which places the participant at unacceptable risk or prevent participation in the study based on Investigator assessment.

What this trial measures

  • Number of participants with adverse events (AEs)Up to 112 weeks
  • Number of participants with serious adverse events (SAEs)Up to 112 weeks
  • Number of participants with AEs meeting protocol defined dose limiting toxicity (DLT) criteriaUp to 28 days
  • Number of participants with AEs leading to study intervention discontinuationUp to 104 weeks
  • Number of deathsUp to 108 weeks